

First Quarter 2010 Earnings Call

Supplemental Slides



HEALTHSOUTH

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current views with respect to future events and financial performance. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2009, and our Form 10-Q for the quarter ended March 31, 2010, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated May 4, 2010, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.

Table of Contents

Q1 2010 Highlights	4
High-Quality Care	5
Revenues (Q1 2010 vs. Q1 2009).....	6
Expenses (Q1 2010 vs. Q1 2009)	7
Adjusted Consolidated EBITDA (Q1 2010 vs. Q1 2009).....	8
Adjusted Income per Diluted Share (Q1 2010 vs. Q1 2009).....	9
Net Cash Provided by Operating Activities (Q1 2010 vs. Q1 2009).....	10
Adjusted Free Cash Flow (Q1 2010 vs. Q1 2009)	11
Debt Outstanding and Liquidity	12
2010 Guidance	13 - 14
Business Outlook	15
Growth	16
Appendix	17
Discharge Growth - Historical.....	18
Cost-Effective Care	19
Readmission Rates	20
Regulatory Uncertainty	21
Revenues (Sequential) & Payment Sources (Q1 2010 vs. Q1 2009)	22
Expenses (Sequential)	23
Operational and Labor Metrics	24
Debt Profile.....	25
Interest Rate Swaps.....	26
Non-Operating Cash/Tax Position.....	27
Outstanding Share Summary	28
US GAAP Reconciliations	29 - 30

Q1 2010 Highlights

- ✓ **Revenue growth of 3.8%**
 - Driven by pricing, payor mix, higher patient acuity, and higher discharge volume

- ✓ **Discharge growth of 1.1%**
 - Steep ramp-up in January, due to strong December discharges
 - Weather-related disruption to discharge patterns in February
 - Strong March discharge growth

- ✓ **High-quality, cost-effective patient care**
 - Continued disciplined expense management and labor productivity gains
 - Continued emphasis on quality outcomes


- ✓ **Leverage ratio reduced to 4.2x⁽¹⁾ from 4.3x at year-end.**

⁽¹⁾ Based on trailing four quarter Adjusted Consolidated EBITDA of \$391.0 million; reconciliation to GAAP provided on slides 29 through 30.

High-Quality Care

FIM Gain = Change in Functional Independent Measurement (based on an 18 point assessment) from Admission to Discharge


FIM Gain



* Average = Expected, Risk-adjusted FIM Change Average

LOS Efficiency = Functional gain divided by length of stay

LOS Efficiency



** Average = Expected, Risk-adjusted LOS Efficiency

Source: UDSmr Database – On Demand
Reports: Q1 2010 Report

Revenues (Q1 2010 vs. Q1 2009)

(Millions)	Q1 2010	Q1 2009	Favorable (Unfavorable) Change
Inpatient	\$ 451.8	\$ 431.3	4.8%
Outpatient and other	39.2	41.6	(5.8%)
Consolidated net operating	<u>\$ 491.0</u>	<u>\$ 472.9</u>	<u>3.8%</u>
 (Actual Amounts)			
Discharges	27,998	27,699	1.1%
Net patient revenue / discharge	\$ 16,137	\$ 15,571	3.6%

- **Inpatient revenue growth was driven by:**
 - 2.5% Medicare market basket increase effective October 1, 2009
 - Discharge growth of 1.1% quarter-over-quarter
 - Increase in percentage of Medicare patients treated
- **Outpatient revenue declined primarily as a result of 10 fewer outpatient satellite clinics quarter over quarter.**

Expenses (Q1 2010 vs. Q1 2009)

(Millions)	Q1 2010	Q1 2009	Favorable/ (Unfavorable) Change
Salaries and benefits	\$ 241.9	\$ 233.3	(3.7%)
Percent of net operating revenues	49.3%	49.3%	0 bps
EPOB (employees per occupied bed)	3.41	3.47	1.7%
Hospital-related expenses	\$ 113.7	\$ 114.1	0.4%
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	23.2%	24.1%	90 bps
General and administrative	\$ 22.5	\$ 21.8	(3.2%)
(excludes stock-based compensation)			
Percent of net operating revenues	4.6%	4.6%	0 bps

- Disciplined expense management
- Solid labor productivity as reflected in EPOB

Adjusted Consolidated EBITDA⁽¹⁾ (Q1 2010 vs. Q1 2009)

(Millions)	Q1 2010	Q1 2009	2009
Net operating revenues	\$ 491.0	\$ 472.9	\$ 1,911.1
Operating expenses:			
Salaries and benefits	241.9	233.3	948.8
Hospital-related expenses:			
Other operating expenses	66.9	66.9	271.4
Supplies	28.3	27.4	112.4
Occupancy costs ⁽²⁾	11.6	12.0	47.3
Provision for doubtful accounts	6.9	7.8	33.1
	<u>113.7</u>	<u>114.1</u>	<u>464.2</u>
General and administrative expenses ⁽³⁾	22.5	21.8	91.1
Equity in nonconsolidated affiliates	2.6	2.5	4.6
Other income ⁽⁴⁾	0.7	0.5	4.8
Noncontrolling interests ⁽⁵⁾	(9.8)	(8.3)	(33.4)
Adjusted Consolidated EBITDA	\$ 106.4	\$ 98.4	\$ 383.0

Adjusted Consolidated EBITDA increased \$8.0 million, or 8.1%, Q1 2010 vs. Q1 2009

(1) Reconciliation to GAAP provided on slides 29 through 30.

In arriving at Adjusted Consolidated EBITDA, the following were excluded from line items:

(2) Restructuring charges associated with closed outpatient satellite clinics of \$0.0, \$0.0, and \$0.3 million, respectively, which reduced occupancy costs.

(3) Stock-based compensation expense of \$3.8, \$3.7, and \$13.4 million, respectively, which reduced general and administrative expenses.

(4) Impairments related to investments of \$0.0, \$0.7 and \$1.4 million, respectively, which increased other income.

(5) Noncontrolling interests related to discontinued operations of \$0.0, \$0.3 and \$0.6 million, respectively, which reduced noncontrolling interests expense.

Adjusted Income per Diluted Share ⁽¹⁾ (Q1 2010 vs. Q1 2009)

(Millions, except per share data)	<u>Q1 2010</u>	<u>Q1 2009</u>	<u>Change</u>	
Adjusted income from continuing operations ⁽¹⁾	\$ 51.9	\$ 39.7	\$ 12.2	30.7%
Weighted average diluted shares outstanding	108.0	100.9	7.1	7.0%
	<u>Per Share</u>		<u>Per Share</u>	
Adjusted income from continuing operations per diluted share ⁽¹⁾	\$ 0.48	\$ 0.39	\$ 0.09	23.1%

- **The improvement was driven by:**
 - Higher Adjusted Consolidated EBITDA
 - Lower interest expense as a result of lower debt balances and a lower LIBOR rate
- **5 million shares were issued on September 30, 2009, related to the 2006 securities litigation settlement.**

⁽¹⁾ Reconciliation to GAAP provided on slides 29 through 30.

Net Cash Provided by Operating Activities (Q1 2010 vs. Q1 2009)

Reconciliation of Adjusted Consolidated EBITDA ⁽¹⁾ to Net Cash Provided by Operating Activities

	<u>Q1 2010</u>	<u>Q1 2009</u>	<u>2009</u>
Adjusted Consolidated EBITDA	\$ 106.4	\$ 98.4	\$ 383.0
Provision for doubtful accounts	6.9	7.8	33.1
Professional fees—accounting, tax, and legal	(2.9)	(4.8)	(8.8)
Interest expense and amortization of debt discounts and fees	(30.5)	(34.4)	(125.8)
UBS Settlement proceeds, gross	-	100.0	100.0
Equity in net income of nonconsolidated affiliates	(2.6)	(2.5)	(4.6)
Net income attributable to noncontrolling interests in continuing operations	9.8	8.3	33.4
Amortization of debt discounts and fees	1.7	1.6	6.6
Distributions from nonconsolidated affiliates	2.1	1.5	8.6
Current portion of income tax (expense) benefit	(2.1)	0.3	7.3
Change in assets and liabilities	(0.7)	9.0	(0.8)
Change in government, class action and related settlements liability	(0.8)	(1.7)	(11.2)
Other operating cash used in discontinued operations	(2.2)	(0.5)	(13.5)
Other	(0.3)	0.1	(1.2)
Net cash provided by operating activities	<u>\$ 84.8</u>	<u>\$ 183.1</u>	<u>\$ 406.1</u>

⁽¹⁾ Notes on page 30.


Adjusted Free Cash Flow (Q1 2010 vs. Q1 2009)

Reconciliation of Net Cash provided by Operating Activities to Adjusted Free Cash Flow

(Millions)	Q1 2010	Q1 2009	2009
Net cash provided by operating activities	\$ 84.8	\$ 183.1	\$ 406.1
Impact of discontinued operations	2.2	0.5	13.5
Net cash provided by operating activities of continuing operations	87.0	183.6	419.6
Capital expenditures for maintenance	(5.6)	(7.5)	(34.1)
Net settlements on interest rate swaps	(11.9)	(8.5)	(42.2)
Dividends paid on convertible perpetual preferred stock	(6.5)	(6.5)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(11.1)	(8.5)	(32.7)
Non-recurring items:			
UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys	-	(73.8)	(73.8)
Cash paid for professional fees - accounting, tax and legal	2.9	4.8	15.3
Cash paid for government, class action and related settlements	0.8	1.7	11.2
State and federal income tax refunds related to prior periods	(6.6)	(49.0)	(63.7)
Adjusted free cash flow	\$ 49.0	\$ 36.3	\$ 173.6

Debt Outstanding and Liquidity

(\$ Billions)



Debt to EBITDA 6.3x 6.3x 5.3x 4.3x 4.2x ⁽¹⁾

Liquidity

	Mar. 31 2010	Dec. 31, 2009
Cash Available	\$ 116.8	\$ 80.9
Revolver Total Line	\$ 400.0	\$ 400.0
Less:		
– Draws	-	-
– Letters of credit	-	-
Available	\$ 400.0	\$ 400.0
Total Liquidity	\$ 516.8	\$ 480.9


Year-End 2011 Goal: 3.5x to 4.0x

⁽¹⁾ Based on trailing four quarter Adjusted Consolidated EBITDA of \$391.0 million; reconciliation to GAAP provided on slides 29 through 30.

2010 Guidance: Adjusted Consolidated EBITDA ⁽¹⁾

Guidance

Based on the results of the first quarter, the Company expects its 2010 full-year performance will be at the high end of the guidance range.



Considerations


- ✓ IT “pilot” investment
- ✓ Integration of acquisitions
- ✓ Start-up costs at two new hospitals
- ✓ TeamWorks investment

⁽¹⁾ Reconciliation to GAAP provided on slides 29 through 30.

2010 Guidance: Adjusted Earnings per Diluted Share⁽¹⁾

Guidance

Based on the results of the first quarter, the Company expects its 2010 full-year performance will be at the high-end of the guidance range.



Considerations

- ✓ \$3 million of additional stock-based compensation expense
- ✓ 5 million more diluted shares (Securities Litigation Settlement)
- ✓ 3-month LIBOR

⁽¹⁾ Reconciliation to GAAP provided on slides 29 through 30.

Business Outlook

Deleveraging, Growth, Reform and Sector Regulation

	2010	2011	2012	2013
Deleveraging	3.5x to 4.0x Debt to EBITDA (by YE 2011) (Exclusive of any E&Y settlement)			
Growth	Organic growth through capacity expansion and de novos (\$60+ million in 2010)			
	IRF acquisitions/joint ventures			
Reform	Market basket minus 25 bps		Acquisitions of other, complementary post-acute services	
	1.Pricing		Market basket minus 10 bps and productivity adjustment	
	2.Bundling		Pilot/Demonstration Projects	
Sector Regulation	<ul style="list-style-type: none"> • LTCH: admission criteria; 25% Rule; MMSEA extension • Home Health: outliers; reimbursement methodology 			

Growth

Target Cash pay-back

Capacity expansions:

- 100+ beds 2010



2 – 4 years ⁽¹⁾

De novos:

<u>Location</u>	<u>Installed Beds</u>	<u>Operational Date</u>
Mesa, AZ	40 Beds	Q3 2009
Loudoun County, VA	40 Beds	Q2 2010
Bristol, VA	25 Beds	Q3 2010



6 - 7 years ⁽²⁾

Acquisitions/Joint Ventures:

- Acquired the rehabilitation unit in Altoona, PA, through a newly formed joint venture and relocated its operations to one of our hospitals. (Q4 2009)
- Expanded joint venture with St. Vincent Health System in Little Rock, AR, through the purchase of a 23-bed rehabilitation unit. (Q1 2010)
- Entered into a definitive agreement to purchase Desert Canyon Rehabilitation Hospital, a 50-bed inpatient rehabilitation hospital located in southwest Las Vegas, NV. (close Q2 2010)



6 - 7 years


⁽¹⁾ Average investment per bed: \$100 K to \$250 K

⁽²⁾ Average investment per bed: ~ \$450 K.




Appendix

Discharge Growth - Historical



- ✓ HealthSouth's volume growth has outpaced competitors'
- ✓ TeamWorks = standardized sales & marketing
- ✓ Capacity expansions will help facilitate organic growth:
 - 100+ beds will be added in 2010.



(1) Data provided by UDS_{MR}, a data gathering and analysis organization for the rehabilitation industry; represents ~ 65-70% of industry, including 90 HealthSouth sites.

(2) Includes 90 consolidated HealthSouth inpatient rehab hospitals and six long-term acute-care hospitals.

Cost-Effective Care

CMS Fiscal Year 2010 IRF Rate Setting File Analysis ⁽¹⁾

	Freestanding ⁽²⁾	Units ⁽²⁾	Total	HealthSouth Hospitals ⁽²⁾
Number of IRFs	228	953	1,181	94
Average # of Discharges per IRF	649	237	316	822
Outlier Payments as % of Total Payments	1.32%	4.08%	3.00%	0.43%
Average Estimated Total Payment per Discharge for FY 2010	\$16,452	\$16,741	\$16,626	\$15,996
Average Estimated Cost per Discharge for FY 2010	\$14,021	\$17,207	\$15,945	\$12,633

Notes:

- (1) All data provided was filtered and compiled from the Centers for Medicare and Medicaid Services (CMS) Fiscal Year 2010 IRF rate setting final rule file found at http://www.cms.hhs.gov/InpatientRehabFacPPS/07_DataFiles.asp#TopOfPage. The data presented was developed entirely by CMS and is based on its definitions which are different in form and substance from the criteria HealthSouth uses for external reporting purposes. Because CMS does not provide its detailed methodology, HealthSouth is not able to reconstruct the CMS projections or the calculation.
- (2) The CMS file contains data for each of the 1,181 inpatient rehabilitation facilities used to estimate the policy updates for the FY 2010 Final IRF-PPS Rule. Most of the data represents historical information from the CMS fiscal year 2008 period and does not reflect the same HealthSouth hospitals in operation today. The data presented was separated into three categories: Freestanding, Units, and HealthSouth. HealthSouth is a subset of Freestanding and the Total.

Readmission Rates

Post-Acute Care ("PAC") Setting	Percent Discharged from Hospital to PAC Setting	Percent Rehospitalized after Using PAC Setting	Percent Died in PAC Setting
Skilled Nursing Facility	17.3%	22.0%	5.4%
Home Health	16.0%	18.1%	0.8%
Long-Term Care Hospital	1.0%	10.0%	15.5%
Inpatient Rehabilitation	3.2%	9.4%	0.4%
Inpatient Psychiatric	0.5%	8.7%	0.4%
Hospice	2.1%	4.5%	82.2%
TOTAL	40.0%	18.0%	6.2%

Note: Use of home health care and hospice is based on care that starts within three days of discharge. Other PAC care starts within one day of discharge. Home health use includes episodes that overlap an inpatient stay.

Source: Medicare Payment Advisory Commission, "A Data Book: Healthcare spending and the Medicare program," Chart 9-3 (June 2008)

Regulatory Uncertainty

Future Regulatory Risk	IRF	SNF	LTCH	HH
1. Re-basing payment system	No	Yes; RUGS IV delayed until 10/01/11 (per PPACA)	No	Yes; would be required as part of PPACA starting in 2014
2. Major outlier payment adjustments	No	No	Yes; will occur when MMSEA relief expires (short stay outliers)	Yes; 10% cap per agency; 2.5% taken out of outlier pool (per PPACA)
3. Upcoding adjustments	No	Yes; occurring in FY 2010	Yes; occurring in FY 2010 and proposed (-2.5%) for FY 2011	Yes; occurring in CYs 2010 and 2011
4. Patient criteria	No; 60% Rule already in place	No	Study dictated as part of MMSEA	PPACA requires a "face-to-face" encounter between physicians (or clinicians working with them) and patients before HH services are prescribed
5. Healthcare Reform <ul style="list-style-type: none"> - Market basket update reductions - Productivity adjustments - Bundling - Independent Medicare Advisory Board - New quality reporting requirements - Value based purchasing 	<ul style="list-style-type: none"> - Known - Begins 2012 - Pilot to be established by 2013 - FY 2019 - Begins 2014 - Pilot begins 2016 	<ul style="list-style-type: none"> - Known - Begins 2012 - Pilot to be established by 2013 - FY 2015 - N/A - Post 2012 	<ul style="list-style-type: none"> - Known - Begins 2012 - Pilot to be established by 2013 - FY 2019 - Begins 2014 - Pilot begins 2016 	<ul style="list-style-type: none"> - Known - Begins 2015 - Pilot to be established by 2013 - CY 2015 - N/A - Post 2012
6. Other	N/A	N/A	25% Rule will be reinstated when MMSEA moratorium expires	N/A

Sources: Healthcare Reform Bill (PPACA, HERA), CMS Regulatory published rules and MMSEA

Revenues (Sequential)

(Millions, except percent)	Q1 2010	Q4 2009	Favorable (Unfavorable) Change
Inpatient	\$ 451.8	\$ 445.7	1.4%
Outpatient and other	39.2	40.5	(3.2%)
Consolidated net operating	<u>\$ 491.0</u>	<u>\$ 486.2</u>	<u>1.0%</u>
(Actual Amounts)			
Discharges	27,998	28,772	(2.7%)
Net patient revenue / discharge	\$ 16,137	\$ 15,491	4.2%

Payment Sources (Q1 2010 vs. Q1 2009)

	Q1 2010	Q1 2009
Medicare	70.4%	67.8%
Medicaid	1.8%	2.2%
Workers' compensation	1.6%	1.7%
Managed care and other discount plans ⁽¹⁾	21.7%	22.4%
Other third-party payors	2.2%	3.3%
Patients	1.1%	1.2%
Other income	1.2%	1.4%
Total	<u>100.0%</u>	<u>100.0%</u>

⁽¹⁾ Managed Medicare revenues represent ~ 7% and 8% of total revenues for Q1 2010 and Q1 2009, respectively, and are included in "Managed care and other discount plans."

Expenses (Sequential)

(Millions, except percent)	<u>Q1 2010</u>	<u>Q4 2009</u>	<u>Favorable (Unfavorable) Change</u>
Salaries and benefits	\$ 241.9	\$ 243.7	0.7%
Percent of net operating revenues	49.3%	50.1%	80 bps
EPOB (employees per occupied bed)	3.41	3.55	3.9%
Hospital related expenses	\$ 113.7	\$ 119.2	4.6%
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	23.2%	24.5%	130 bps
General and administrative	\$ 22.5	\$ 24.7	8.9%
(excludes stock-based compensation)			
Percent of net operating revenues	4.6%	5.1%	50 bps

Operational and Labor Metrics ⁽¹⁾

	Q1 2010	Q4 2009	Q3 2009	Q2 2009	Q1 2009	2009
	(In Millions)					
Net patient revenue-inpatient	\$ 451.8	\$ 445.7	\$ 429.2	\$ 437.2	\$ 431.3	\$ 1,743.4
Net patient revenue-outpatient and other revenues	39.2	40.5	41.2	44.4	41.6	167.7
Net operating revenues	<u>\$ 491.0</u>	<u>\$ 486.2</u>	<u>\$ 470.4</u>	<u>\$ 481.6</u>	<u>\$ 472.9</u>	<u>\$ 1,911.1</u>
	(Actual Amounts)					
Discharges ⁽²⁾	27,998	28,772	28,125	28,379	27,699	112,975
Outpatient visits	255,445	265,067	281,913	291,944	283,621	1,122,545
Average length of stay	14.6	14.0	14.3	14.4	14.6	14.3
Occupancy %	69.2%	66.5%	67.0%	69.4%	69.9%	67.3%
# of licensed beds	6,563	6,572	6,507	6,454	6,443	6,572
Occupied beds	4,542	4,370	4,360	4,479	4,504	4,423
Full-time equivalents (FTEs) ⁽³⁾	15,416	15,428	15,528	15,590	15,469	15,504
Contract labor	82	64	60	120	143	97
Total FTE and contract labor	<u>15,498</u>	<u>15,492</u>	<u>15,588</u>	<u>15,710</u>	<u>15,612</u>	<u>15,601</u>
EPOB ⁽⁴⁾	3.41	3.55	3.58	3.51	3.47	3.53


(1) Numbers have been reclassified to reflect current continuing operations.

(2) Represents discharges from HealthSouth's 90 consolidated hospitals and 6 LTCHs.

(3) Excludes approximately 400 full-time equivalents, who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.

(4) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

Debt Profile



	Debt Balances ⁽¹⁾		2010 YTD Debt Reduction
	Mar. 31, 2010	Dec. 31, 2009	
Advances under \$400 million revolving credit facility, March 2012	\$ -	\$ -	\$ -
Term loan facility - March 2013, 2015	749.4	751.3	(1.9)
Bonds payable:			
10.75% Senior Notes due 2016	495.0	494.9	0.1
8.125% Senior Notes due 2020	285.2	285.2	-
Other bonds payable	1.8	1.8	-
Other notes payable	28.0	28.0	-
Capital lease obligations	97.9	101.3	(3.4)
Total	\$ 1,657.3	\$ 1,662.5	\$ (5.2)
Debt to EBITDA ⁽²⁾	4.2x	4.3x	

(1) The Company had \$116.8 million in cash and cash equivalents as of March 31, 2010.

(2) Based on trailing four quarter Adjusted Consolidated EBITDA of \$391.0 million; reconciliation to GAAP provided on slides 29 through 30.

Interest Rate Swaps

(Millions)

Floating Rate Debt Balances	Mar. 31, 2010	Floating Interest Rate							
Advances under \$400 million revolving credit facility	\$ -	Libor plus 300							
Term Loan facility due 2013	450.9	Libor plus 225							
Term Loan facility due 2015 ⁽¹⁾	298.5	Libor plus 375 ⁽¹⁾							
Total	<u>\$ 749.4</u>								
Swap Settlement	Notional Amount	Cash payment if LIBOR = 0.30%							
		2010				2011			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
<u>Does not Qualify for Hedge Accounting</u> ⁽²⁾									
Net notional amount of interest rate swaps ⁽³⁾ Receive 3 month Libor and pay 5.22% fixed	\$ 884.0	11.9	11.2	11.1	11.0	10.9	-	-	-
<u>Does Qualify for Hedge Accounting</u> ⁽⁴⁾									
Notional amount of the interest rate swap Receive 3 month Libor and pay 2.6% fixed	\$ 100.0		-	-	-		0.6	0.6	0.6
Notional amount of the interest rate swap Receive 3 month Libor and pay 2.9% fixed	\$ 100.0		-	-	-		0.7	0.7	0.7

⁽¹⁾ In October 2009, the credit agreement was amended. The maturity for \$300 million of the term loan has been extended to 2015. The extended portion of the term loan will bear an interest rate of Libor plus 375.

⁽²⁾ Cash settlements flow through investing activities.

⁽³⁾ In June 2009, we entered into a receive-fixed rate swap as a mirror offset to \$100.0 million of the \$1,056 million interest rate swap.

⁽⁴⁾ Forward-starting interest rate swaps (designated as cash flow hedges). Cash settlements will flow through operating activities as part of interest expense.

Non-Operating Cash/Tax Position

Cash Refunds as of Mar. 31, 2010

- Federal tax recoveries virtually complete.
- State tax refunds in progress.
 - Approx. \$6.5 million received in Q1 2010.
 - Approx. \$1.1 million net receivable on the balance sheet.

GAAP Considerations

- HealthSouth's balance sheet currently reflects a valuation allowance for the potential value of NOLs and future deductions. The valuation allowance is approximately \$893 million.
- GAAP tax rate will net to small amount for foreseeable future as there will be a reduction in the valuation allowance when NOLs are utilized.

Future Cash Tax Payments

- Expect to pay about \$5-7 million per year of income tax.
 - State income tax.
 - Alternative Minimum Tax (AMT).
- The Company does not expect to pay significant federal income taxes for the next 10-12 years, due to approximately \$905 million in deferred tax assets as of 12/31/09 outlined in the 2009 Form 10-K. The majority of the deferred tax assets is related to NOLs.
 - At this time, we do not believe the use of NOLs will be limited before they expire, however, no assurances can be provided.
- HealthSouth is not currently subject to an annual use limitation (AUL) under the Internal Revenue Code section 382.
- If we experienced a "change of ownership" as defined by the Internal Revenue Code section 382, we would be subject to an AUL, which is equal to the value of the company at the time of the "change of ownership" multiplied by the long-term tax exempt rate.

Outstanding Share Summary

(Millions)

	Weighted Average for the Period			
	Q1 2010	Q1 2009	Year-End 2009	Year-End ⁽¹⁾ 2008
Basic Shares outstanding ^{(2) (3)}	92.7	87.5	88.8	83.0
Diluted Shares outstanding ^{(2) (3) (4)}	108.0	100.9	103.3	96.4

	End of Period			
	Q1 2010	Q1 2009	Year-End 2009	Year-End ⁽¹⁾ 2008
Basic Shares outstanding ^{(2) (3)}	92.7	87.5	92.6	87.4
Diluted Shares outstanding ^{(2) (3) (4)}	108.0	100.9	107.8	100.7

Notes:

- (1) Completed an equity offering for 8.8 million shares on June 27, 2008.
- (2) Does not include 2.0 million warrants issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. In connection with this transaction, we issued warrants to the lender to purchase two million shares of our common stock. Each warrant has a term of ten years from the date of issuance and an exercise price of \$32.50 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented.
- (3) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are now included in the outstanding shares. The warrants at a strike price of \$41.40 were not assumed exercised for the dilutive shares outstanding because they are anti-dilutive in the periods presented.
- (4) The difference between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.

Three Months Reconciliation of Net Income to Adjusted Income from Continuing Operations and Adjusted Consolidated EBITDA ^{(1) (3) (4)}

(In Millions, Except per Share Data)	Q1 2010		Q1 2009		2009	
		Per Share ⁽²⁾		Per Share ⁽²⁾		Per Share ⁽²⁾
Net income	\$ 50.5	\$ 0.54	\$ 53.5	\$ 0.61	\$ 128.8	\$ 1.45
Loss (income) from discontinued operations, net of tax, attributable to HealthSouth	3.1	\$ 0.03	3.0	0.03	(1.5)	(0.02)
Net income attributable to noncontrolling interests	(9.8)	(0.11)	(8.6)	(0.10)	(34.0)	(0.38)
Income from continuing operations attributable to HealthSouth	<u>43.8</u>	<u>0.47</u>	<u>47.9</u>	<u>0.55</u>	<u>93.3</u>	<u>1.05</u>
Government, class action, and related settlements	-	-	(15.9)	(0.18)	36.7	0.41
Professional fees – accounting, tax, and legal	2.9	0.03	4.8	0.05	8.8	0.10
Gain on early extinguishment of debt	-	-	(1.8)	(0.02)	-	-
Loss on interest rate swaps	4.3	0.05	5.0	0.06	19.6	0.22
Adjustment for prior period amounts in tax provision	0.9	0.01	(0.3)	(0.00)	(8.8)	(0.10)
Adjusted income from continuing operations	<u>51.9</u>	<u>0.56</u>	<u>39.7</u>	<u>0.45</u>	<u>149.6</u>	<u>1.68</u>
Adjustment for dilution		(0.08)		(0.06)		(0.23)
Adjusted income from continuing operations per diluted share		<u>\$ 0.48</u>		<u>\$ 0.39</u>		<u>\$ 1.45</u>
Current period amounts in tax provision	1.6		1.5		5.6	
Interest expense and amortization of debt discounts and fees	30.5		34.4		125.8	
Depreciation and amortization	<u>18.3</u>		<u>17.4</u>		<u>70.9</u>	
	102.3		93.0		351.9	
Other adjustments per the Company's credit agreement:						
Impairment charges, including investments	-		0.7		1.4	
Net noncash loss on disposal of assets	-		1.0		3.5	
Loss on early extinguishment of debt	0.3		-		12.5	
Stock-based compensation expense	3.8		3.7		13.4	
Other	-		-		0.3	
Adjusted Consolidated EBITDA	<u>\$ 106.4</u>		<u>\$ 98.4</u>		<u>\$ 383.0</u>	
Weighted average common shares outstanding:						
Basic		<u>92.7</u>		<u>87.5</u>		<u>88.8</u>
Diluted		<u>108.0</u>		<u>100.9</u>		<u>103.3</u>

(1) (2) (3) (4) – Notes on page 30.

Reconciliation Notes

1. Adjusted income from continuing operations and Adjusted Consolidated EBITDA are non-GAAP financial measures. The Company's leverage ratio (Total Consolidated Debt to Adjusted Consolidated EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize adjusted income from continuing operations as a financial measure and Adjusted Consolidated EBITDA and leverage ratio as liquidity measures on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating these adjusted measures, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth above.
2. Per share amounts for each period presented are based on basic weighted average common shares outstanding for all amounts except adjusted income from continuing operations per diluted share, which is based on diluted weighted average shares outstanding. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.
3. Adjusted income from continuing operations per diluted share and Adjusted Consolidated EBITDA are two components of our guidance.
4. The Company's Credit Agreement allows certain other items to be added to arrive at Adjusted Consolidated EBITDA, and there may be certain other deductions required.